20092010年我院口服降糖药临床应用和经济学分析.docVIP

20092010年我院口服降糖药临床应用和经济学分析 　　[摘要] 目的：了解2009～2010年我院口服降糖药的使用状况及发展趋势，为口服降糖药的合理用药提供参考。方法：采用金额排序法和DDD分析法，对我院口服降糖药的用药金额、用药频度（DDDs）、日均费用（DDDc）等进行统计与分析。结果：2009～2010年口服降糖药的品种、数量及销售金额等逐年增长；2010年用药金额前3位为阿卡波糖、瑞格列奈、格列齐特（2009年前二者无变化，第3位为格列美脲）；用药频度前3位保持为二甲双胍、格列美脲、阿卡波糖；日均费用前3位为罗格列酮、阿卡波糖、瑞格列奈。结论：我院临床口服降糖药应用中，糖苷酶抑制剂阿卡波糖、磺脲类药物的格列齐特和双胍类药物的二甲双胍均为因其疗效好、不良反应较少等居主导地位，为一线降糖药物新型药物，有较大的发展空间。我院口服降糖药的总体应用较为合理。 　　[关键词] 糖尿病；口服降糖药；限定日剂量；用药频度；日均费用 　　[中图分类号] R969.3 [文献标识码] C [文章编号] 1673-7210（2011）11（b）-151-02 　　 　　Application and economic analysis of oral hypoglycemic agents in our hospital in 2009-2010 　　XIAO Shuo, WANG Zhongquan 　　The Affiliated Jingzhou Hospital of Tongji Medical School, Huazhong University of Science and Technology, Hubei Province, Jingzhou 434020, China 　　[Abstract] Objective: To evaluate the usage of oral hypoglycemic drugs in our hospital in order to provide reference for rational use of drugs in clinic. Methods: DDDs, sales volume and daily expenses of oral hypoglycemic agents in our hospital from 2009 to 2010 were analyzed with the method of amount of money rank and DDD analysis. Results: The variety, quantity and amount of oral hypoglycemic drugs increased year by year. Acarbose, Repaglinide and Gliclazide were the top 3 in 2010, which differed a little with those in 2009 (the third was Glimepiride); DDDs of Metformin, Glimepiride and Acarbose were the top 3; DDDc of Rosiglitazone, Acarbose and Repaglinide were the top 3. Conclusion: In our hospital, Acarbose of Glycosidase inhibitors, Gliclazide of Sulfonylureas and Metformin of Biguanide are the most common because their good effects and few adverse reactions. The usage of oral hypoglycemic agents in our hospital is rational. 　　[Key words] Diabetes; Oral hypoglycemic agents; Defined daily dose; DDDs; DDDc 　　 　　糖尿病是世界范围内最常见的慢性病之一，需要持续的医学治疗和患者的自我控制，以防止与减少急性并发症。如果将糖耐量异常统计在内，我国现有糖尿病患者约9 200万例[1]。糖尿病血糖的控制极其复杂，临床上对其做出了各类尝试，现将我院2009～2010年口服降糖药的临床应用情况进行统计并加以分析，为其合理用药提供参考。 　　1 资料与方法 　　1.1 一般资料 　　从我院医院管理系统（HIS）提取的2